-

Tempus Accelerates Its EHR Integration Scope With Epic

Tempus expands its existing provider EHR integrations to offer physicians seamless access to its genomic testing

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, announced that it is working with Epic to offer providers in-workflow integrations at scale. Since its founding, Tempus has strived to provide physicians seamless access to next-generation sequencing and the accompanying data to support them in providing personalized patient care.

Through Epic’s Genomics module, Tempus has been paving the way with live EHR integrations that embed test ordering and discrete genomic data delivery into the existing clinical workflow, with 8 institutions already live and a number underway. Tempus’ initial work with Epic made it the first somatic sequencing lab in the country creating these types of integrations.

“Tempus understands our need for efficient, streamlined ordering and reliable discrete results all in one place so that we can promptly implement the actionable results for our patients,” said Karen Huelsman, MS, LGC, Precision Oncology Lead at TriHealth Precision Oncology. “More than that, Tempus continually works with our precision oncology team to optimize the integration and apply Epic’s Genomics module components to fit our specific, changing needs.”

Tempus is building on that existing work to accelerate and scale this endeavor. In 2022, Epic and Tempus expect to support large-panel genomic sequencing testing across the Epic network. This new capability is designed to reduce integration timelines from months to weeks and make it significantly easier for health systems to enable Tempus testing options within their Epic EHR.

"We realized that we could significantly reduce the amount of time physicians spend ordering Tempus' smart diagnostics and viewing results at the point of care, ultimately freeing up more time for them to spend with their patients,” said Terron Bruner, Chief Commercial Officer of Tempus. “Epic introduced the technology we needed to make these kinds of integrations not only possible, but also seamless for providers, like TriHealth, seeking these solutions.”

“Our work with Tempus presents a tremendous opportunity to advance precision medicine by empowering providers and patients with insights from integrated genomic data,” said Alan Hutchison, Vice President of Population Health at Epic. “Together we can deliver on the promise of precision medicine and positively impact early detection, treatment, and survival.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Hanah Heintzelman
hanah.heintzelman@tempus.com

Tempus


Release Versions

Contacts

Hanah Heintzelman
hanah.heintzelman@tempus.com

More News From Tempus

Tempus Announces Multi-Year Collaboration with Moderna and Merck

CHICAGO--(BUSINESS WIRE)--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know...

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid. At this year’s congress, Tempus will showcase clinical research revealing insights in cancer biology, treatment response and patient outcomes across solid tumors, including prostate, breast, non-small cell lung cancer (NSCLC), renal cell carcinoma and gynecologic mali...

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation (MR). MR is a common form of heart valve disease where blood leaks backward through the mitral valve. Because early stages are often asymptomatic or manifest as no...
Back to Newsroom